Ethical, Legal, Social, and Policy Implications of Workplace Genomic Testing

Information

  • Research Project
  • 10268974
  • ApplicationId
    10268974
  • Core Project Number
    R01HG010679
  • Full Project Number
    5R01HG010679-02
  • Serial Number
    010679
  • FOA Number
    PA-17-444
  • Sub Project Id
  • Project Start Date
    9/25/2020 - 4 years ago
  • Project End Date
    8/31/2024 - 6 months ago
  • Program Officer Name
    STERLING, RENE
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/30/2021 - 3 years ago

Ethical, Legal, Social, and Policy Implications of Workplace Genomic Testing

PROJECT SUMMARY More than 157 million people in the US receive their healthcare insurance through employer health plans. In some cases, employers are offering voluntary workplace genomic testing (wGT) through such health plans. Indeed, a growing number of employers are considering offering such services to their employees. However, wGT raises substantial legal and policy concerns including privacy of genetic information. Given the expectation that wGT will become more prevalent in the future, there is an urgent need to understand its benefits and risks. Thus, we propose to assess the ethical, legal, social, and policy implications of wGT using a mixed-methods approach and engaging multiple stakeholders at different stages of the study. We have assembled an interdisciplinary team of national experts to study the following: 1) Examine employers' perspectives on wGT through: a) Landscape analysis to ascertain the prevalence and distribution of wGT among US companies; and b) Semi-structured interviews of key executives of a range of companies who are offering or declined to offer wGT to identify employers' motivations, challenges, and perceived benefits of implementing wGT. 2) Investigate employees' views on and response to wGT through a: a) National web-survey of employed adults to assess their attitudes and beliefs about wGT; b) Baseline web-survey of both wGT takers (n=500) and decliners (n=500) in partnership with a large healthcare system to assess perceptions of the benefits, risks, and limitations of wGT; and c) Follow-up web-survey of wGT takers to examine the psychological, behavioral, and economic impact of wGT. 3) Employ a combination of approaches, including a deliberative workshop and modified Delphi process to distill the findings of Aim 1 and 2, ultimately yielding an empirically informed normative assessment of wGT. We will engage a broad set of stakeholders including employers, employees, labor and business organizations, and policy makers regarding potential harms and benefits of wGT. Impact: The findings from this study will reveal the prominent issues and stakeholder perspectives in an understudied area of genomic testing and identify key ethical, legal, social, and policy considerations for employees and employers, and suggest practice and policy options for implementation and governance of wGT.

IC Name
NATIONAL HUMAN GENOME RESEARCH INSTITUTE
  • Activity
    R01
  • Administering IC
    HG
  • Application Type
    5
  • Direct Cost Amount
    650503
  • Indirect Cost Amount
    177630
  • Total Cost
    828133
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    172
  • Ed Inst. Type
  • Funding ICs
    NHGRI:828133\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    JACKSON LABORATORY
  • Organization Department
  • Organization DUNS
    042140483
  • Organization City
    BAR HARBOR
  • Organization State
    ME
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    046091523
  • Organization District
    UNITED STATES